COVID-19–VACCINATED KIDNEY TRANSPLANT RECIPIENTS ARE ESPECIALLY VULNERABLE TO EMERGING SARS-CoV-2 VARIANTS

Most kidney transplant recipients do not mount strong neutralizing antibody responses to beta and delta variants following standard COVID-19 vaccination.

Highlight

• New research indicates that many kidney transplant recipients may not be adequately protected against emerging SARS-CoV-2 variants with the standard COVID-19 vaccination regimens currently used in the healthy general population.

Washington, DC (December 22, 2021) — Kidney transplant recipients tend to mount impaired antibody responses against emerging SARS-CoV-2 variants after standard two-dose COVID-19 vaccination, according to new research published in CJASN. This is true even for transplant recipients with detectable antibody responses against the original SARS-CoV-2 strain in commercially available assays.

Because kidney transplant recipients are at high risk for SARS-CoV-2 infection and more severe COVID-19 disease, SARS-CoV-2 vaccination is strongly recommended in these patients. Studies indicate that kidney transplant recipients mount lower antibody responses following SARS-CoV-2 vaccination compared with healthy individuals, however. As most of these studies were performed when SARS-CoV-2 wildtype and B.1.1.7 (alpha) strains were the predominant variants, it’s unclear whether the findings translate to the current situation with the emerging variants of concern B.1.351 (beta) and B.1.617.2 (delta).

To investigate, a team led by Claudius Speer, MD (Heidelberg University Hospital, in Germany) conducted a prospective two-center study of 173 kidney transplant recipients and 166 healthy controls with different SARS-CoV-2 vaccination schedules between December 2020 and June 2021.

Following vaccination, fewer kidney transplant recipients developed neutralizing antibodies against SARS-CoV-2 than healthy controls. After the second vaccine dose, anti-S1, anti-receptor-binding domain, and surrogate neutralizing antibodies—all different
types of antibodies against various aspects of SARS-CoV-2—were detectable in 30%, 27%, and 24% of kidney transplant recipients, respectively. This compared with 100%, 96%, and 100% in healthy controls.

Neutralization against B.1.1.7 (alpha) was detectable in all 36 of 173 kidney transplant recipients who mounted antibody responses against the original SARS-CoV-2 strain. However, when these 36 kidney transplant recipients were tested for their antibody responses to emerging variants after vaccination, only 64% and 67% showed neutralization against B.1.351 (beta) and B.1.617.2 (delta), respectively. Neutralization against different variants was significantly higher in healthy controls, with all individuals showing neutralization against all tested variants.

“We discovered that a large proportion of kidney transplant recipients is not adequately protected against the emerging variants B.1.351 (beta) and B.1.617.2 (delta) with the standard vaccination regimens currently used in the healthy general population,” said Dr. Speer. “Additional vaccinations appear to be required in kidney transplant recipients to maintain high levels of neutralizing antibodies, especially when B.1.617.2 (delta) or other variants with partial escape from neutralizing antibodies are prevalent.”

An accompanying editorial notes that additional strategies beyond booster shots are needed to protect kidney transplant recipients who do not respond to the standard 2-dose vaccine regimen. “In the absence of seroconversion, the use of anti SARS-CoV-2 monoclonal antibodies might be the solution to protect this fragile population against the emergence of variants of concern,” the authors wrote.

An accompanying Patient Voice editorial provides the perspective of a patient who has been living with a kidney transplant for 25 years.

Study authors include Louise Benning, MD, Christian Morath, MD, Marie Bartenschlager, Christian Nusslag, MD, Florian Kälble, MD, Mirabel Buylaert, MD, Matthias Schaier, MD, Jörg Beimler, MD, Katrin Klein, MD, Julia Grenz, Paula Reichel, MD, Asa Hidmark, PhD, Gerald Ponath, PhD, Maximilian Töllner, Marvin Reineke, Susanne Rieger, MD, Burkhard Tönshoff, MD, Paul Schnitzler, PhD, Martin Zeier, MD, Caner Süsäl, MD, Ralf Bartenschlager, MD, and Claudius Speer, MD.

Disclosures: Funding for this study has been received by the “Dietmar Hopp Stiftung” with the grant number 1DH2111111. The authors have no financial disclosures.


The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit www.asn-online.org.

# # #